Ann: Operational Update, page-3

In mid-May the company announced that it would provide a detailed update on the Anagrelide project. Unfortunately, at the beginning of June, SUDA’s CEO became ill and was hospitalised in the USA from the 10th June returning to Australia for further treatment with final release from hospital in Australia on 6th July.Since the middle of July, Mr Carter has been progressively increasing his time at the office whilst his health has been continually improving. We are glad to report that as of 25th July he is back at work full time.During this period, Mr Carter continued to communicate with the board and management to ensure that the key projects and partnering discussions remained on track. All key operations and the release of any material information was not impacted. The board can confirm that it was in line with the ASX Listing Rules requirements.The experience and depth of SUDA’s executive team ensured that the company continued to run effectively, and the board was happy to see that SUDA’s detailed delegation program was effective and ensured that during the loss of a key person, such as the CEO, there was minimal impact on the overall critical company operations.The impact of Mr Carter’s illness did affect some of the non-critical aspects of the day to day operations, including the writing and release of project updates.



onwards and upwards. Glad to hear he’s back to full health and able to return back to work.